- Report
- February 2022
- 100 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Report
- January 2022
- 40 Pages
India
From €1422EUR$1,500USD£1,188GBP
- Report
- January 2022
- 40 Pages
Saudi Arabia
From €1422EUR$1,500USD£1,188GBP
- Report
- August 2024
- 123 Pages
China
From €1706EUR$1,800USD£1,425GBP
- Report
- January 2024
- 129 Pages
United States
€3602EUR$3,800USD£3,009GBP
- Report
- June 2022
- 114 Pages
Global
From €4734EUR$4,995USD£3,955GBP
€4502EUR$4,750USD£3,761GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2018
- 16 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2018
- 13 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2018
- 8 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €474EUR$500USD£396GBP
- Report
- January 2025
- 96 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- October 2024
- 97 Pages
Global
From €3500EUR$3,956USD£3,026GBP

The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less Read more